Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2022 Q1- Text added to 2022 Q2
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
New words:
asciminib, beneficial, bosutinib, broad, cytogenetic, dasatinib, diagnosed, differentiated, difficult, DUET, escalation, exhibit, expansion, fasting, glycemic, hematologic, imatinib, intolerant, leukemic, minimal, mortality, mutation, newly, nilotinib, overcome, overweight, PK, prevalence, refractory, resistance, resistant, site, SOC
Valuein 2022 Q1 filing- Value in 2022 Q2 filing
Original filings
Filing view